Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 5

Methotrexate-induced cutaneous ulceration in patients with erythrodermic mycosis fungoides

Authors Breneman DL, Storer TJ, Breneman JC, Mutasim DF

Published 10 October 2008 Volume 2008:4(5) Pages 1135—1141


Debra L Breneman1, Timothy J Storer2, John C Breneman3, Diya F Mutasim4

1University of Cincinnati Medical Center, Dept of Dermatology, Cincinnati, Ohio, USA; 2Smith Clinic, Delaware, Ohio, USA; 3University of Cincinnati Medical Center, Dept of Radiology, Division of Radiation Oncology, Cincinnati, Ohio, USA; 4University of Cincinnati Medical Center, Dept of Dermatology, Cincinnati, Ohio, USA

Abstract: Methotrexate-induced cutaneous ulceration has rarely been reported in patients with mycosis fungoides. We report 4 patients with mycosis fungoides who developed cutaneous ulceration as an initial manifestation of methotrexate toxicity. Methotrexate dose at the time of ulceration ranged from 10–60 mg. All 4 patients were erythrodermic, which may have predisposed them to this toxic effect. It is important to recognize cutaneous ulceration as an uncommon, but potentially serious, side effect of methotrexate in these patients, and to differentiate it from ulceration due to progressive lymphoma.

Keywords: mycosis fungoides, methotrexate, ulceration, cutaneous T-cell lymphoma, toxicity

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Readers of this article also read:

Management of pediatric corneal limbal dermoids

Pirouzian A

Clinical Ophthalmology 2013, 7:607-614

Published Date: 28 March 2013

Changes in neurophysiologic markers of visual processing following beneficial anti-VEGF treatment in macular degeneration

Vottonen P, Kaarniranta K, Pääkkönen A, Tarkka IM

Clinical Ophthalmology 2013, 7:437-442

Published Date: 27 February 2013

Use of ibandronate in the prevention of skeletal events in metastatic breast cancer

Bianca Devitt, Sue-Anne McLachlan

Therapeutics and Clinical Risk Management 2008, 4:453-458

Published Date: 11 April 2008

Obstructive sleep apnea and cardiovascular risk

Punginathn Dorasamy

Therapeutics and Clinical Risk Management 2007, 3:1105-1111

Published Date: 15 January 2008

How should we measure medication adherence in clinical trials and practice?

Jeannie K Lee, Karen A Grace, Terri G Foster, Monica J Crawley, Goldina I Erowele, et al

Therapeutics and Clinical Risk Management 2007, 3:685-690

Published Date: 15 September 2007

Etanercept in the treatment of rheumatoid arthritis

Boulos Haraoui, Vivian Bykerk

Therapeutics and Clinical Risk Management 2007, 3:99-105

Published Date: 15 March 2007